ワカバヤシ　ムネヒロ   Wakabayashi Munehiro   若林　宗弘    所属   東邦大学  医学部 医学科（大森病院）    職種   助教
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Paclitaxel plus cetuximab versus nivolumab for patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a retrospective analysis
掲載誌名	正式名：International Journal of Clinical Oncology ISSNコード：13419625
掲載区分	国外
巻・号・頁	30(3),pp.480-488
著者・共著者	Hiroyuki Kodama, Shigenori Kadowaki, Yasunobu Ishizuka, Munehiro Wakabayashi, Tomoki Sakakida, Kazunori Honda, Toshiki Masuishi, Yukiya Narita, Hiroya Taniguchi, Masashi Ando, Toshihiro Kishikawa, Hoshino Terada, Shintaro Beppu, Daisuke Nishikawa, Hidenori Suzuki, Nobuhiro Hanai, Kei Muro
発行年月	2025/03
概要	Background: Nivolumab is the standard treatment for platinum-refractory recurrent/metastatic head and neck squamous cell carcinoma (R/M-HNSCC). Several studies have reported the efficacy of paclitaxel plus cetuximab (PC) combination therapy in this patient population. Methods: We conducted a retrospective analysis of patients with platinum-refractory R/M-HNSCC treated with nivolumab or PC at our institution between January 2015 and March 2022. Eligibility criteria included histologically confirmed HNSCC, ECOG performance status (PS) 0-2, with platinum-refractory R/M disease. Results: The baseline characteristics of the 56 patients (21 PC/35 nivolumab) were ECOG PS 1-2 (76/54%), metastatic sites ≥ 2 (33/46%), local recurrence (62/23%), and median tumor size (43.2/26.2 mm). Median progression-free survival (mPFS) tended to favor PC over nivolumab (4.3/2.7 months, hazard ratio [HR]: 0.7, p = 0.41), and median overall survival tended to be inferior for PC (8.0/23.2 months, HR: 1.58, p = 0.20). Grade 3/4 adverse events were more frequent with PC (29/6%), and the most prevalent were leukopenia (19%) for PC and liver dysfunction (6%) for nivolumab. Subsequent treatment with PC and nivolumab was administered to 75% and 72% of patients, respectively; the mPFS of these patients was significantly lower with PC (1.6/9.2 months, HR: 9.9, p < 0.001). Conclusion: Both PC and nivolumab are viable treatment options for platinum-refractory R/M-HNSCC, though their efficacy and safety profiles should be carefully considered.